Previous 10 | Next 10 |
2024-06-11 13:25:29 ET The major market averages have shifted lower for the most part on Tuesday ahead of key inflation data and the Federal Reserve’s latest rate decision, but some stocks are still flashing signs of being overbought according to the relative strength index technical...
2024-06-11 11:52:50 ET More on Novo Nordisk Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Novo Nordisk: Considerable Growth Beyond Ozempic SA Asks: Is Eli Lilly or Novo Nord...
2024-06-11 11:25:13 ET Summary The BlackRock Enhanced International Dividend Trust offers attractive geographical diversification and a high level of income with a yield of 7.28%. The BGY closed-end fund's lower yield compared to similar funds appears to be partly due to its less ...
(NewsDirect) Compared to their non-orphan counterparts, orphan drugs have consistently outpaced growth and have become a major part of pharma’s mainstream business. The U.S. FDA's orphan drug designation, established under the Orphan Drug Act of 1983, encourages the development of trea...
2024-06-11 04:57:00 ET Shares of Structure Therapeutics (NASDAQ: GPCR) shot up more than 50% during the first week of June. The stock market is responding to a positive readout for an experimental weight-management drug the company is working on. Structure Therapeutics is a clin...
2024-06-10 14:38:05 ET More on Eli Lilly, Novo Nordisk SA Asks: Is Eli Lilly or Novo Nordisk a better investment? Is It Possible Eli Lilly Is Breaking Out To New All-Time Highs? Eli Lilly's Growth And Challenges: A Cautious Buy SA Asks: Which weight-los...
2024-06-10 12:48:37 ET Summary Five Keros Therapeutics, Inc. abstracts are expected at the upcoming EHA conference between June 13th -16th of 2024, showcasing data using KER-050 for the treatment of patients with low-risk myelodysplastic syndrome. The company has already met with ...
2024-06-10 12:06:11 ET Summary Hims & Hers stock has easily outperformed the market over the past year, surging almost 130%. Hims & Hers' personalized care platform is a critical growth driver poised to expand further. Hims & Hers is targeting the weight loss drugs...
2024-06-10 10:00:05 ET Jasper Hellweg from Argus Research issued a price target of $160.00 for NVO on 2024-06-10 08:41:00. The adjusted price target was set to $160.00. At the time of the announcement, NVO was trading at $142.88. The overall price target consensus is at ...
2024-06-09 08:47:48 ET Summary Eli Lilly's tirzepatide shows potential in resolving metabolic dysfunction-associated steatohepatitis without worsening fibrosis. GLP-1 drugs pose a serious threat to Madrigal's Rezdiffra, potentially dominating the MASH market. Madrigal's financ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...
2024-07-14 05:20:00 ET Two pharma juggernauts, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) , are picking up speed in their preparations for an epic battle to control the market for weight loss drugs. The prize for the victor will be a larger market share of what may b...